Lupin inks licensing pact with Takeda to sell gastro drug Vonoprazan in India

Vonoprazan is used in treatment of reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of the treatment for Helicobacter pylori eradication.

Pharma major Lupin Ltd announced on Wednesday that it has entered into a non-exclusive patent licensing agreement with Takeda to bring Vonoprazan tablets, a novel gastrointestinal drug, to the Indian market.

The drug will be sold under the brand name Lupivon and will come in two doses — 10mg and 20mg. According to Lupin, Vonoprazan has been approved by the Drug Controller General of India (DCGI) for the treatment of reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of the treatment for Helicobacter pylori eradication.

According to the agreement, Takeda has granted Lupin the non-exclusive rights to commercialise Vonoprazan in India.

"We are very pleased to bring Vonoprazan to the market as a novel treatment option for acid peptic disorders. This move strengthens our gastroenterology portfolio and aligns with our commitment to introducing innovative medicines to address the unmet needs of our patients," Rajeev Sibal, president of India Region Formulations at Lupin, said.

Lupin share price traded under selling pressure in Wednesday's trade to quote at Rs 2,230.60 per share on the NSE, down 1.75 percent.

In the last three years, the stock moved higher by 134.36 percent, as per data available on the BSE.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.